Stealth Biotherapeutics Inc.

Mayo Foundation for Medical Education and Research

Stealth Peptides International, Inc.

Good Samaritan Institute for Research and Education

Heart Institute Good Samaritan Hospital

Henry Ford Health System

Wilson, D. Travis

D Travis Wilson

Scott M Duncan

Hani Naief Sabbah

Mark J Bamberger

Robert A Kloner

Marc W Andersen

Kenneth Borow

Stephen C Textor

Sharon Hale

Brian Blakey

Lilach O Lerman

Elizabeth Mead

Mark Bamberger

The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.

Methods and compositions for the prevention and treatment of disease

The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.

Methods and compositions for detecting and diagnosing diseases and conditions

The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.

Methods and compositions for the prevention or treatment of Barth Syndrome

The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.

Aromatic-cationic peptides and uses of same

The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2'6′-Dmt-Lys-Phe-NH.

Processes for preparing pharmaceutically relevant peptides

The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.

Methods and compositions for increasing the dose of a chemotherapeutic agent

Methods and compositions for the prevention or treatment of Barth syndrome

The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.

Methods for treating heart disease in a subject with Friedreich's ataxia by an aromatic-cationic peptide

The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Aromatic-cationic peptides and methods for using same

The present technology provides methods for detecting and diagnosing diseases and conditions characterized by mitochondrial dysfunction using monocytes as an indicator of the dysfunction.

Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening

The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.

Methods for the regulation of matrix metalloproteinase expression

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6&#x2032;-dimethyl-Tyr-D-Arg-Phe-Lys-NH, Phe-D-Arg-Phe-Lys-NH, or D-Arg-2&#x2032;,6&#x2032;-Dmt-Lys-Phe-NH.

Growing community of inventors

Newton, MA, United States of America

D Travis Wilson